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Abstract 
Clathrin, a cytosolic protein composed of heavy and light chain subunits, assembles into a 
vesicle coat, controlling receptor-mediated endocytosis. To establish clathrin light chain (CLC) 
function in vivo, we engineered mice lacking CLCa, the major CLC isoform in B-lymphocytes, 
generating animals with CLC-deficient B cells. In CLCa-null mice, the germinal centers have 
fewer B cells and they are enriched for IgA-producing cells. This enhanced switch to IgA 
production in the absence of CLCa was attributable to increased TGFβR2 signaling resulting 
from defective endocytosis. Internalization of CXCR4 but not CXCR5 was affected in CLCa-null 
B cells and CLC depletion from cell lines affected endocytosis of δ-opioid receptor, but not β2-
adrenergic receptor, defining a role for CLCs in uptake of a subset of signaling receptors. This 
first instance of clathrin subunit deletion in vertebrates demonstrates that CLCs contribute to 
clathrin’s role in vivo by influencing cargo selectivity, a function previously assigned exclusively 
to adaptor molecules.  
Keywords: Clathrin light chain, endocytosis, antibody isotype switch, TGFβ, G-protein-coupled 
receptors 
 
Significance  
Clathrin forms coats on vesicles that control receptor endocytosis, thereby influencing cell 
signaling. The contribution of the clathrin light chain subunits to this process in mice was 
addressed by deleting the gene encoding the predominant light chain form (CLCa) present in B 
lymphocytes. CLCa-null mice have B cells with altered antibody production and aberrant 
development due to defects in endocytosis of signaling receptors that influence these processes. 
Only a subset of signaling receptors was found to depend on clathrin light chains for their 
endocytosis, demonstrating that light chain subunits contribute to selection of particular clathrin-
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coated vesicle cargo. This study clarifies a role for the light chains in vivo, showing they 
contribute properties to the clathrin coat that regulate cargo uptake. 
 
Introduction 
Clathrin-coated vesicles (CCVs) influence cell signaling by selecting membrane cargo during 
endocytosis (1). Clathrin consists of three clathrin heavy chain (CHC17) subunits, each 
associated with a clathrin light chain (CLC), configured into a three-legged triskelion. Clathrin 
triskelia self-assemble into a latticed coat that traps membrane-associated adaptor molecules, 
which recruit cargo into the CCV through recognition of defined protein motifs. Cargo specificity 
is therefore determined by adaptor binding, but recent studies in vitro have suggested that the 
CLC subunits can also influence cargo selection. Vertebrates have two CLC isoforms, CLCa 
and CLCb, encoded by separate genes, CLTA and CLTB (1). Depletion of both isoforms from 
tissue culture cells by siRNA treatment showed that CLCs are not required for clathrin-mediated 
uptake of classic CCV cargoes such as transferrin receptor (TfR), epidermal growth factor 
receptor or LDL-receptor (2-4). CLCs were, however, implicated in uptake of three G-protein 
coupled receptors (GPCRs) (5). CLCs are also required for uptake of large particles, including 
some viruses and bacteria (6, 7). These roles for CLCs in cargo selection and their general 
contribution to clathrin function have been a matter of speculation for some time, with 
indications from in vitro experiments that CLCs regulate clathrin assembly (8) and tensile 
strength of the clathrin lattice (1, 9). To assess such roles for CLCs in clathrin function in vivo, 
we made mutant mice that lack the CLTA gene and report their phenotype here. 
In mammals, CLCa and CLCb are ~60% identical in protein sequence (1). Shared sequences of 
22 and 10 residues respectively, mediate binding to the actin-organizing huntingtin-interacting 
proteins (mammalian Hip1 and Hip1R, yeast Sla2p) (10-12) or the leucine-rich repeat kinase 2 
(LRRK2) (13). Mammalian cell culture experiments and genetic studies in yeast and flies have 
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shown that, through these interactions, CLCs participate in several pathways that could 
significantly affect clathrin function in vertebrates. These include clathrin-mediated endocytosis 
from membranes under tension (14, 15), formation of clathrin-actin interfaces during cell 
adhesion (16), clathrin-mediated recycling in cell migration (2) and endosome function during 
Drosophila eye development (13). 
In vertebrates, both CLTA and CLTB gene products undergo alternative mRNA splicing to 
generate four possible forms of CLCa and two of CLCb (1). Neurons express the highest 
molecular weight forms of both CLCs. The lowest molecular weight forms predominate in non-
neuronal tissue (17, 18) and vertebrate tissues maintain characteristic levels of CLCa and CLCb 
(17, 19). Here, using an updated quantification approach, we established that there are two 
CLC expression patterns, with most tissues expressing equal levels of CLCa and CLCb, while 
CLCa expression is dominant in lymphoid tissue. Consequently, B cells in our CLTA-knockout 
mice were effectively CLC-deficient, allowing us to address the functional consequence of CLC 
loss in vertebrates through analysis of immunological phenotypes. We observed that B cells 
from CLTA knockout mice had defects in internalization of transforming growth factor-β receptor 
2 (TGFβR2) and C-X-C chemokine receptor 4 (CXCR4). Though not all signaling receptors 
were affected by CLCa loss, defects in receptor internalization accounted for phenotypes 
observed in the knockout animals. Thus, CLCs play a significant role in cargo selection by 
CCVs in vivo by influencing uptake of specific signaling receptors. 
 
Results 
Tissues maintain characteristic CLCb levels upon CLCa loss, resulting in CLC-deficient 
lymphocytes. To investigate the physiological function of CLCs in vivo, we generated a CLCa 
null heterozygote (CLTAko/+) by crossing mice with exon 1 of CLTA flanked by LoxP sites to 
mice expressing Cre recombinase under transcriptional control of the ACTB gene promoter (Fig. 
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S1 A and B). Half of the homozygous CLTAko/ko mice produced by heterozygote mating died 
within a week of birth. Surviving CLTAko/ko homozygotes (KO mice) had no detectable CLCa 
protein in all tissues analyzed (Fig. S1 C and D) and loss of CLCa did not affect protein levels of 
the CHC17 subunit (Fig. S1 D and E). For WT and KO mice, we quantified the amount of each 
CLC isoform in brain, heart, liver and spleen tissue by immunoblotting using isotype-specific 
antibodies (Fig. 1A and Fig. S1 G and H). As previously observed for bovine brain tissue (17), 
WT murine brain tissue expressed neuronal splice variants of both CLCa and CLCb in excess of 
the other spliced forms of CLCs. Brain, heart and liver had equal amounts of CLCa and CLCb, 
while spleen expressed predominantly CLCa. Analysis of purified B and T lymphocytes detected 
CLCa in these cells and no CLCb protein (Fig. 1B), suggesting that the small amount of CLCb 
detected in spleen derived from non-lymphoid cells. B cells had more clathrin than T cells, as 
revealed by CHC17 and CLCa levels (Fig. 1B). We did not see compensatory increase of CLCb 
protein levels in the KO mice, except in liver tissue (Fig. 1A). Tissue levels of mRNA encoding 
each isoform and CHC17 were consistent with protein levels detected (Fig. 1 C-E and Fig. S1F). 
Over all, these results indicate there are two types of tissue, one with clathrin coats formed from 
triskelia with CLCa and CLCb, and the other in which CLCa is the predominant light chain of 
CCVs. Furthermore, expression of each CLC isotype appears to be independently regulated, 
such that B and T lymphocytes from the KO animals are effectively CLC-deficient. 
 
Genetic loss of CLCa increases the proportion of germinal center (GC) B cells 
expressing IgA but reduces numbers of GC B cells. We focused on B cell function in the KO 
animals to define the role of CLCs in vivo. A sign of B cell function is the formation of germinal 
centers (GCs) in follicles within the spleen and other lymphoid organs such as Peyer’s patches 
(Pp) and lymph nodes (LNs) (20). In GCs, B cells proliferate and differentiate to produce higher 
affinity antibodies and switch isotypes (21, 22). We found that KO mice had an increased 
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frequency of IgA-expressing GC B cells in Pp compared to WT controls, as well as a variable 
but, on average, two-fold reduction in IgG1-expressing B cells (Fig. 2A, gating shown in Fig. S2 
A and B). To determine whether this is an intrinsic B cell defect or is caused by changes in the 
stroma, we studied mixed bone marrow (BM) chimeras produced by reconstitution of sub-
lethally irradiated C57BL/6 mice (CD45.1+). For each transplant, KO or WT (CD45.2+) BM cells 
were combined 1:1 with WT C57BL/6 (CD45.1+CD45.2+) BM cells (B6), producing KO/B6 or 
WT/B6 mixed chimeras. The co-transplanted B6 (CD45.1+CD45.2+) cells served as a control for 
transplant variation to which properties of the donor KO or WT (CD45.2+) cells were compared. 
As for full KO mice, the KO donor (CD45.2+) cells generated a greater proportion of IgA-
expressing GC B cells but fewer IgG1-expressing GC B cells than co-transplanted B6 
(CD45.1+CD45.2+) cells in KO/B6 mixed chimeras (Fig. 2B, gating shown in Fig. S2 C and D). In 
WT/B6 mixed chimeras, donor WT (CD45.2+) cells had similar proportions of IgA- and IgG1-
expressing GC B cells to co-transplanted B6 (CD45.1+CD45.2+) cells (Fig. 2B). The contribution 
of KO cells to the GC B cell population was about 50% of their contribution to the naive follicular 
compartment in three lymphoid organs examined (Fig. 2C, gating in Fig. S2C), whereas in 
WT/B6 chimeras, the percentage of WT (CD45.2+) donor B cells in the GCs was similar to the 
follicular compartments (Fig. 2C). This reduced presence of KO B cells in the GCs suggested a 
defect in GC B development or maintenance, upon CLCa loss. These data from BM chimeras 
further indicate that the perturbations in isotype switching by KO GC B cells are lymphocyte-
intrinsic defects and that CLCa is required for normal isotype class switching to IgA and IgG1. 
 
CLCa regulates internalization and signaling of transforming growth factor β receptor 2 
(TGFβR2). Selective in vivo deletion of TGFβR2 from murine B cells was shown to reduce IgA-
expressing cells and increase IgG1-expressing B cells (23), suggesting that our KO phenotype 
might result from increased TGFβR2 signaling. Consistent with this hypothesis, B cells from Pp 
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and spleen of KO mice had higher TGFβR2 surface levels than WT mice (Fig. 3A and Fig. S3A), 
while surface levels of the B cell marker, B220, were unchanged in KO mice (Fig. S3 A and B). 
Relative to co-transplanted B6 (CD45.1+CD45.2+) cells, elevated surface TGFβR2 was also 
observed for transplanted CD45.2+ KO B cells in the KO/B6 mixed chimeras, but not for B cells 
from the WT (CD45.2+) donor in WT/B6 chimeras (Fig. 3B and Fig. S3C). Again, a difference in 
surface level was not seen for B220 on KO-derived B cells (Fig. S3 C and D). These BM 
chimera phenotypes demonstrated that dysregulation of TGFβR2 surface expression is a cell-
intrinsic defect and confirm that this defect does not affect B220. 
In the KO B cells, increased TGFβR2 at the B cell surface was not due to increased production 
of mRNA or protein (Fig. 3 C and D), suggesting that clathrin-mediated endocytosis of TGFβR2 
(24, 25) is CLC-dependent. This pathway could not be studied using B cells from the KO mice 
because the TGFβR2 antibody signal was insufficient to assess receptor internalization. 
Therefore, we tested TGFβR2 uptake (Fig. 3E) in HEK293T cell lines transiently transfected 
with TGFβR2-IRES-GFP and co-transfected with siRNA targeting both CLCa and CLCb to 
recapitulate the CLC-deficient state of the KO B cells. TGFβR2 internalization was significantly 
reduced in CLC-depleted HEK293T cells compared to cells treated with non-targeting (control) 
siRNA and we confirmed that TGFβR2 endocytosis was impaired in cells treated with siRNA 
targeting CHC17 to deplete all clathrin (24). In the same siRNA-treated TGFβR2-transfected 
cells, uptake of endogenous transferrin receptor (TfR) was sensitive to CHC17 depletion but not 
CLC-dependent, as reported (3) (Fig 3F). Together our FACS and internalization studies 
indicate that TGFβR2, like several GPCRs (5), is CLC-dependent cargo for CCVs, while B220 is 
like the CCV cargo whose surface expression is CLC-independent. 
We assessed TGFβR2 signaling through Smad2/3 in the KO B cells because this signaling 
regulates class switch to IgA in B cells (23, 26-28). Smad signaling is initiated by 
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phosphorylation of R-Smad2 and R-Smad3 when TGFβR1 is activated by TGFβR2 binding 
upon TGFβR1 engagement with ligand from the TGFβ superfamily (24). Consistent with 
activation of this pathway, we observed elevated levels of phospho-Smad2/3 in splenic B cells 
and total splenocytes isolated from KO mice relative to cells isolated from WT mice (Fig. 3G and 
Fig. S3 E and F). Thus, in the presence of endogenous concentrations of TGFβ, the higher 
levels of surface TGFβR2 lead to enhanced Smad signaling, establishing a molecular 
mechanism for the observed increase in B cells expressing IgA in the KO mice. 
 
CLCa influences ligand-induced uptake of CXCR4 but not CXCR5. Since we observed 
increased surface TGFβR2 on KO B cells, we assessed surface levels of other receptors critical 
for B cell function in GCs (29). GC B cells from Pp and mesenteric LNs (mLNs) of KO mice had 
higher surface levels of CXCR4 compared to equivalent B cells from WT controls, whereas 
B220 levels were not affected in the KO (Fig. S4 A and B), as previously noted (Fig. S3 A and 
B). Analysis of B cells from lymphoid compartments of BM chimeras also showed that donor KO 
(CD45.2+) cells had elevated CXCR4 levels while donor WT (CD45.2+) cells had similar levels 
(Fig. 4A and Fig. S4 C and D) compared to co-transplanted B6 (CD45.1+CD45.2+) cells. In 
contrast, neither KO nor WT (CD45.2+) donors displayed increased surface CXCR5 or B220 
(Fig. 4 A and B). Increased surface CXCR4 was explained by reduced internalization in 
response to stromal cell-derived factor 1 (SDF1 or CXCL12) observed for both GC and follicular 
B cells from the mLNs of KO mice (Fig. 4C and Fig. S4E) compared to equivalent WT cells. 
Upon SDF1 exposure, KO-derived B cells from BM chimeras had consistently higher CXCR4 
levels than co-transplanted B6 cells, while WT-derived GC and follicular cells had comparable 
levels to co-transplanted B6 cells (Fig. S4F). In contrast, B cells from KO mice exposed to 
CXCR5 ligand (CXCL13) showed no difference in internalization response compared to B cells 
from WT mice (Fig. 4D and Fig. S4G) and KO-derived B cells showed comparable CXCR5 
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levels to B6-derived donor cells from BM chimeras after CXCL13 treatment, indicating no 
difference in CXCR5 uptake behavior by KO cells (Fig. S4H). 
 
CLC depletion from cell lines establishes selectivity for different CCV cargo. Finding that 
CLCa regulates the B cell surface levels of TGFβR2 and CXCR4, but not CXCR5 and B220, 
inspired us to investigate CLC dependence for uptake of other cargoes. Given that three 
GPCRs were previously shown to depend on CLCs for uptake (5), we focused on two additional 
GPCRs, β2-adrenergic receptor and δ-opioid receptor known to depend on clathrin for uptake 
(30, 31), but for which the role of CLCs had not been examined. Using siRNA, HEK293 cells 
that stably express either N-terminally FLAG-tagged β2-adrenergic receptor (F-β2AR), or N-
terminally FLAG-tagged δ-opioid receptor (F-DOR) were made CLC-deficient by CLCa and 
CLCb knockdown leaving residual CHC17, or completely clathrin-deficient by CHC17 
knockdown (Fig. S5 A and B). Ligand-induced internalization of the tagged receptors was then 
assessed. CLC depletion, as well as CHC17 depletion, impaired ligand-induced endocytosis of 
F-DOR (Fig. 5A and Fig. S5C). As expected, uptake of endogenous TfR was not affected by 
CLC depletion, though sensitive to CHC17 depletion (Fig. 5B and Fig. S5D). Surprisingly, 
ligand-induced endocytosis of F-β2AR was not affected by CLC depletion, similar to the 
behavior of TfR in the same cells, though internalization of both receptors was affected by 
CHC17 depletion (Fig. 5 C and D and Fig. S5 E and F). Together, our data reveal that CLCs are 
required for uptake of a subset of signaling receptors, such as TGFβR2, CXCR4 and DOR, but 
are dispensable for internalization of other receptors, such as β2AR and CXCR5.  
 
DISCUSSION 
We produced a CLCa-knockout mouse to probe the physiological function of CLCs. This is the 
first study to address clathrin subunit function in vertebrates by gene deletion, and defines a key 
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role for CLCs in selection of cargo for CCVs in vivo. B cells from CLCa-null mice are effectively 
CLC-deficient, since CLCa expression is dominant in lymphoid cells, and their phenotypes 
revealed that cargoes requiring CLCs for endocytosis are important for B cell function. Reduced 
internalization of TGFβR2 by CLCa null B cells increased Smad2 signaling at the plasma 
membrane, generating a higher percentage of IgA-producing B cells in KO animals compared to 
WT. Though IgA switching is a known consequence of TGFβ signaling (23, 26-28), the role of 
TGFβR2 endocytosis in regulating signaling has been debated (24, 32). Our results support a 
role for CLC-dependent clathrin-mediated endocytosis in attenuating TGFβR2 signaling, since 
increased surface levels had the functional effect of promoting isotype switching. Our results 
further suggest that increased switching to IgA in the Peyer’s patch occurs at the expense of 
switching to IgG1. We speculate that the elevated TGFβR signaling caused by CLCa loss 
dominates over signaling from factors that promote IgG1 switching (e.g. IL4). This may have 
been most evident in the Peyer’s patch where sufficient amounts of TGFβ are available to 
stimulate elevated surface TGFβRs. 
The reduced frequency of germinal center (GC) B cells in CLCa-null mice could be explained by 
increased surface expression and reduced internalization of CXCR4, which plays a role in cell 
distribution within the GC (29). Additionally, CLCa deficiency might affect internalization of 
sphingosine-1-phosphate receptor 2 (S1PR2), a GPCR that negatively regulates GC B cell 
numbers (33), but lack of reagents to track S1PR2 surface expression prevented us from testing 
this. Thymocytes from the KO mice also had elevated levels of CXCR4, but no obvious changes 
in T cells populations in spleen, lymph nodes or bone marrow were observed (not shown), 
suggesting that the GC B cell defects in the bone marrow chimeras are B cell intrinsic. These 
results further suggest that T cells compensate more readily for surface receptor changes, 
having more redundant regulatory pathways than B cells as a result of their more ancient origins 
(34). 
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Loss of CLCa from B cells did not affect CXCR5 levels or internalization. Thus, CLCs are 
dispensable for uptake of some GPCRs, as further observed in transfected cells, displaying 
CLC-dependent internalization of DOR, but not β2AR. Our findings plus earlier observations 
that CLCs are required for internalization of some GPCRs (5) but not several classical CCV 
cargoes (3, 4) suggest that CLCs are needed for endocytosis depending on the type and/or 
configuration of cargo present in a clathrin-coated pit. Variation in cargo crowding and local lipid 
organization affect membrane-bending properties, which in turn require different coat properties 
for deformation into a vesicle (35). CLCs contribute tensile strength to the clathrin lattice through 
controlling rigidity of the hub region of the triskelion (8, 9) and, in cells, by recruiting the actin-
regulating Hip proteins (2, 6, 8, 15). Thus, CLCs may contribute to uptake of cargoes that pose 
particular membrane-bending challenges. Analogously, Sec13p in COPII-coated vesicles 
contributes structural rigidity that is required to bend membranes with asymmetric cargo, such 
as GPI-anchored receptors (36). Two GPCR cargoes (µ-opioid receptor and CXCR4) that 
require CLCs for endocytosis, are modified by ubiquitin, which attracts specific endocytic 
adaptors to promote uptake by clathrin-coated pits (5, 31, 37). Such aggregation, mediated by 
ubiquitination or other pathways is likely to change membrane-bending properties that could 
then require extra tensile strength provided by CLCs in the clathrin coat. Mutagenesis studies 
suggest that CLC phosphorylation by GRK2 may contribute to regulation of CLC’s role in GPCR 
cargo selection (5). Whether CLC phosphorylation is also involved in uptake of the CLC-
dependent receptors identified here is not yet established. However, CLC-dependent TGFβR 
internalization was observed in the absence of ligand engagement without associated signaling.  
Past studies indicated that vertebrate tissues have characteristic patterns of CLCa and CLCb 
expression (17, 19). These studies used methods that could not distinguish forms of CLCa and 
CLCb that co-migrate by SDS-PAGE analysis. Using new isotype specific antibodies, calibrated 
with recombinantly-expressed protein, we show here that mice have tissues that either express 
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equal amounts of CLCa and CLCb (non-lymphoid), or predominantly CLCa (lymphoid). A 
remaining mystery is why, within all vertebrates, CLCa and CLCb genetic clades are clearly 
distinguishable and each highly conserved (1). Recently, expression of an alternatively spliced 
variant of CLCa during postnatal murine heart development was reported (18), suggesting that 
CLCa has specialized tissue functions, which may explain the 50% post-natal mortality rate of 
the CLCa-null mice. It is notable that of the cell types analyzed here, lymphocytes are 
distinguished from other differentiated cell types by their lack of CLCb, which must change the 
nature of their clathrin. Major distinctions between lymphocytes and the other tissues examined 
are the lack of adherens junction or tight junction formation by lymphocytes and their persistent 
motility, as well as extensive cortical actin. Yeast with similar properties, function with only one 
CLC, which is most homologous to CLCa and is a key player in endocytosis through its 
association with the actin-binding Hip homologue Sla2p. This suggests that CLCa could confer 
a specialized actin-interacting activity that is critical for clathrin function in lymphocytes. Indeed, 
lymphocyte endocytosis and immune synapse formation is dependent on both clathrin and actin 
(38, 39). An alternative possible explanation for the conservation of CLC isoforms is that CLCa 
and CLCb influence cargo selection differently, which could also have tissue-specific and 
physiological consequences.   
 
Materials and Methods 
Production of CLCa-null mice. Our BAC targeting construct, produced by homologous 
recombination in E. coli, contained PGKneo flanked by FRT sites and a loxP site in intron 1 of 
the CLTA gene, with a second loxP site cloned into the 5’ UTR. ES cells were targeted by 
transfection and G418 selection to produce a floxed CLTA gene (CLTAflox), then transfected 
with Flpe-recombinase to excise the PGKneo cassette. Targeted ES cells were injected into 
C57BL/6 mouse blastocysts transferred into foster mothers. Chimeric offspring were mated with 
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C57BL/6 females and germ line transmission of the CLTAflox allele established. CLTAflox/+ 
heterozygotes were mated to ACTB-Cre deleter mice, excising exon 1 to generate the CLTA 
null allele (CLTAko). Heterozygous CLTAko/+ mice were backcrossed onto the C57BL/6 
background, and bred to produce CLTAko/ko homozygous mice (Fig. S1 B). 
Mixed bone marrow chimeras. Mixed bone marrow (BM) chimeric mice were generated by 
intravenous transfer of a 50:50 mixture of BM cells from two different lines of mice into CD45.1+ 
congenic C57BL/6 mice (3 x 106 to 5 x 106 cells transferred per mouse). 50% transferred BM 
was derived from CLTAko/ko (CD45.2+) (KO) mice or CLTA+/+ CD45.2+congenic wild-type 
C57BL/6 (WT) mice and 50% derived from CD45.1+CD45.2+ congenic WT C57BL/6 (B6), to 
generate KO/B6 or WT/B6 chimeric bone marrow mice. Prior to transfer, recipient mice were 
sub-lethally irradiated (2 x 450 rads, 3 hours apart). Mice were analyzed at least 8 weeks after 
reconstitution.  
Splenic B cell and T cell purification. Splenic B and T cells were purified by negative 
selection using magnetic beads. For B cell purification, spleen cells were exposed to anti-CD43-
coated beads (MACS, Miltenyi Biotech). For T cell purification, spleen cells were exposed to a 
cocktail of biotin-conjugated antibodies (anti-Ter119, anti-B220, anti-CD19, anti-CD11b, anti-
Gr1, anti-CD11c) followed by binding to Streptavidin MicroBeads (MACS, Miltenyl Biotech). Cell 
purity was confirmed by FACS. 
Flow cytometry. Spleen, mesenteric lymph node and Peyer's patch cells were isolated and 
labeled for FACS analysis as described previously (29). Antibodies used for GC B cell 
identification, immunoglobulin isotype detection, mixed bone chimeras analysis, and labeling of 
TGFβR2, CXCR4 and CXCR5 are specified in the SI.  
Internalization assays. Internalization assays measured residual receptor remaining on the 
cell surface following incubation at 37°C. Percent internalization was established relative to 
surface labeling of cells maintained at 4°C for the duration of the experiment or relative to cells 
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with no ligand treatment at 37°C, as specified. Background signal of secondary labeling was 
subtracted separately from experimental and control signals. See SI for a detailed protocol. 
Statistical Analysis. Statistical analyses were performed using GraphPad Prism (GraphPad 
Software, Inc). Parametric data were analyzed using two-tailed Student t-tests, one-way or two-
way ANOVA, followed by Bonferroni post hoc tests for multiple comparisons as appropriate 
(95% confidence interval). 
Additional Methods: Details of siRNAs, plasmids, and methods for tissue culture, transfection, 
quantitative immunoblotting and mRNA quantification are in the online SI. 
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FIGURE LEGENDS 
Figure 1. CLC isoform expression in tissues from wild-type and CLCa-null mice. (A) 
Concentrations of CLC isoforms in indicated tissues from wild-type (WT) and CLCa-null (KO) 
mice (mean ± SEM, n=3) determined by quantitative immunoblotting (Fig. S1 G and H). nCLCa 
and nCLCb are neuronal splice variants. (B) B and T lymphocytes isolated from WT murine 
spleens were lysed and analyzed by immunoblotting for expression of proteins indicated (left). 
CLCa (green) and CLCb (red) signals were compared to dilutions of purified human CLCs (total 
protein per lane indicated above). Migration position of molecular mass markers (kilodaltons, 
kD) is indicated. (C) CLCa mRNA levels in indicated tissues from WT mice, normalized to 
mRNA levels for hypoxanthine guanine phosphoribosyl transferase 1 (HPRT1, mean ± SEM, 
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n=3), (Pp, Peyers patch; mLN, mesenteric lymph node). (D) CLCb mRNA levels in indicated 
tissues from WT and KO mice, normalized to mRNA levels for HPRT1 (mean ± SEM of n=3, 
except n=2 for brain cortex). (E) CLCa, CLCb and CHC17 mRNA levels in B and T cells isolated 
from WT spleens, normalized to HPRT1 (mean ± SEM of n=3, **P<0.05, unpaired t-test).  
 
Figure 2. CLCa-null mice have an elevated frequency of IgA-expressing B cells and a 
reduced proportion of germinal center (GC) B cells. (A) Frequency of IgA and IgG1-
expressing GC B cells in Peyer's patches (Pp) of wild-type (WT) and CLCa-null (KO) littermates 
(mean ± SEM, n=19, *P<0.05, **P<0.001, unpaired t test). (B) Frequency of IgA and IgG1-
expressing GC B cells derived from C57BL/6 (B6) donor or KO and WT littermate donors in Pp 
of mixed chimeric mice transplanted with 50% WT B6 plus 50% KO or WT littermate bone 
marrow (mean ± SEM, n>15 from >4 pairs of matched KO and WT donors, **P<0.05, ns :not 
significant, one-way ANOVA). (C) Percentage of donor (WT or KO CD45.2+) cells in the GC B 
compartment compared to their percentage in the corresponding follicular (Fo B) compartment 
in mixed bone marrow chimeras (mean ± SEM; n>27 for mesenteric lymph node (mLN), n>42 
for Pp (33), n>11 for spleen, **P<0.05 , ***P<0.001, unpaired t-test).  
 
Figure 3. CLCa regulates TGFβR2 internalization and signaling. (A) Mean fluorescence 
intensity (MFI) of TGFβR2 surface labeling of follicular (Fo) and germinal center (GC) B cells 
from Peyer’s patches (Pp) and total B cells from spleen of wild-type (WT) and CLCa-null (KO) 
littermates (n>11 for Pp and n=5 for spleen, *P<0.01, **P<0.001, unpaired t test). (B) Ratio of 
the MFI of WT or KO donor cells (CD45.2+) to the MFI of B6 donor cells (CD45.1+CD45.2+) for 
surface labeling of TGFβR2 for Fo B and GC B from WT/B6 and KO/B6 chimeras (mean ± SEM 
of n=10 from at least 3 pairs of different donors for mixed chimera mice, **P<0.05, ***P<0.001, 
unpaired t-test). (C) TGFβR1 and TGFβR2 mRNA levels in spleen B cells of WT and KO 
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littermates, normalized to mRNA levels for hypoxanthine guanine phosphoribosyl transferase 1 
(mean ± SEM of n=3). (D) Lysates (equal protein loading) of B cells from WT and KO littermates 
were analyzed by immunoblotting for TGFβR2 and other proteins indicated by arrowheads (left). 
Migration position of molecular mass markers (kilodaltons, kD) is indicated. (E) HEK293T cells 
were transiently transfected with TGFβR2-IRES-GFP and siRNA targeting CHC17 (blue), CLCa 
and CLCb (CLCab, red) or scrambled siRNA (control). Percent TGFβR2 internalization at 37°C 
over time was quantified after labeling with primary antibody at 4°C and using a secondary 
antibody to detect residual surface receptor relative to cells maintained at 4°C (mean ± SEM of 
n=5 independent experiments, ***P<0.001; P values, Two-way ANOVA followed by Bonferroni 
post test). (F) Internalization of endogenous transferrin receptor (TfR) at 37°C over time 
analyzed by flow cytometry in cells treated as in E (mean ± SEM of n=5 independent 
experiments, ***P<0.001; P values, Two-way ANOVA followed by Bonferroni post test). (G) 
Levels of pSmad2/3 and Smad2/3 in lysates of spleen or B cells from WT and KO littermates 
quantified by immunoblotting, normalized to CHC17 levels relative to total protein loaded 
(representative blots in Fig. S3 E and F) (n=5 for total splenocytes and n=2 for purified spleen B 
cells, *P<0.01, one-way ANOVA).  
  
Figure 4. CLCa-null B cells have increased CXCR4 surface levels and impaired ligand-
induced CXCR4 internalization. (A) Ratios of the mean fluorescence intensity (MFI) of CXCR4 
and B220 on wild-type (WT) or CLCa-null (KO) donor cells (CD45.2+) to MFIs on C57BL/6 (B6) 
(CD45.1+CD45.2+) donor cells for germinal center (GC) B cells from lymphoid tissues indicated 
from WT/B6 and KO/B6 chimeras (mean ± SEM; n=42 for Peyer’s patches, n>11 for spleen, 
from at least 3 pairs of different donors for mixed chimera mice, **P<0.05, ***P<0.001, unpaired, 
t-test). (B) MFI ratios for CXCR5 and B220 on WT or KO donor follicular (Fo B) or GC B cells 
(CD45.2+) relative to B6 donor B cell populations (CD45.1+CD45.2+) from mesenteric lymph 
! 19 
nodes (mLNs) (mean ± SEM; n>11). (C) Percent CXCR4 internalized at 37°C over time after 
addition of SDF1 (relative to surface CXCR4 on control cells similarly treated with PBS) for Fo B 
and GC B cells from mLNs of WT or KO mice (mean ± SEM of n=5 WT and n=6 KO from 2 
independent experiments, *P<0.01, two-way ANOVA with Bonferroni post tests). (D) Percent 
CXCR5 internalized at 37°C over time after addition of CXCL13 (relative to surface CXCR5 on 
control cells similarly treated with PBS) for Fo B and GC B cells from mLNs of WT or KO mice 
(mean ± SEM of n= 5 WT and 5 KO mice, from 2 independent experiments).  
 
Figure 5. CLC depletion impairs δ-opioid receptor internalization but does not affect β2-
adrenergic receptor uptake. (A) Percent FLAG-tagged δ-opioid receptor (FLAG-DOR) or 
transferrin receptor (TfR) internalized at 37°C over time (mean ± SEM of n=4 independent 
experiments, **P<0.01, ***P<0.001, ****P<0.0001; P values, Two-way ANOVA followed by 
Bonferroni post test). (B) Percent FLAG-tagged β2-adrenergic receptor (FLAG-β2AR) or TfR 
internalized at 37°C over time (mean ± SEM of n=3 independent experiments, **P<0.01, 
***P<0.001, ****P<0.0001; P values, Two-way ANOVA followed by Bonferroni post test). FLAG-
tagged receptor uptake was measured on cells treated with agonist (DPDPE for FLAG-DOR 
and isopreteronol for FLAG-β2AR) relative to cells treated with PBS and TfR uptake was 
relative to untreated cells labeled with primary antibody maintained at 4°C. 
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Supplemental Information 
 
Material and Methods 
 
Mice. C57BL/6 (B6) mice were purchased from The Jackson Laboratory. CD45.1+ congenic 
B6 mice were obtained from the National Cancer Institute (01B96; B6-LY5.2/Cr). 
CD45.1+CD45.2+ mice were generated by crossing B6 and Boy/J (Jackson Laboratory, 
002014; B6.SJL-Ptprc a Pepc b/BoyJ) mice. Mice were bred and maintained at the 
Laboratory Animal Research Center at UCSF. The UCSF Institutional Animal Care and Use 
Committee approved all animal experiments. 
 
siRNAs and plasmids. siRNA duplexes were synthesized by Qiagen. Targeting sequences 
for CHC17, CLCa and CLCb were as published (2, 3). Human TGFβR2 (sub-cloned from 
pCMV5B-TGFbeta receptor II wt (N-term HA), Addgene plasmid # 24801) was cloned into 
IRES-GFP in the vector PCL6IEGWO (40).   
 
Tissue culture and transfections. HEK293 cells were cultured in DMEM, supplemented 
with 10% FBS (Hyclone) and antibiotics. For siRNA treatment, cells were plated at ~70% 
confluency, and the following day were transfected with siRNA using the jetPRIME reagent 
(PolyPlus transfection), according to the manufacturer’s protocol. Cells were analyzed 72 
hours after transfection. For TGFβR2 internalization assays, HEK293T cells were co-
transfected with siRNA and TGFβR2-IRES-GFP using jetPRIME reagent (PolyPlus 
transfection). 
 
Immunoblotting. Transfected HEK293 cells were solubilized in lysis buffer (50mM Tris (pH 
7.2), 150mM NaCl, 20mM EDTA, 1% Triton X-100, and EDTA-free protease inhibitors 
(Roche)) and lysate produced by centrifugation to remove nuclei. Protein content of lysates 
was determined using the Pierce BCA Protein Assay kit (number 23225, Thermo Scientific). 
Proteins were resolved on pre-cast SDS-PAGE gels (4-12% acrylamide; Invitrogen), 
transferred onto nitrocellulose membranes (Bio-Rad) and detected by labeling with primary, 
then secondary antibodies. Blots were scanned using the Odyssey Infrared Imaging System 
(LI-COR Biosciences, Lincoln, NE), or by using the ECL system (Amersham Biosciences) 
according to the manufacturers’ protocols. 
          Amounts of the CLC isoforms in tissues were determined by quantitative 
immunoblotting using a previously described protocol (19). Murine tissues were first 
homogenized in lysis buffer (150mM NaCl, 1mM EGTA, 10mM Hepes, 0.5mM MgCl2, 0.02% 
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NaN3, 0.05% PMSF, pH 7.2) containing EDTA-free protease inhibitors (Roche) on ice and 
centrifuged at 1,000 g for 30 min at 4°C. Resulting supernatants were boiled for 10 min and 
centrifuged at 10,000 g for 10 min at 4°C. This protocol leaves boiling-resistant CLCs in 
solution and causes CHC and almost all other proteins to precipitate. To analyze lymphocyte 
subpopulations, purified splenic B and T cells were incubated in lysis buffer, then centrifuged 
to produce supernatant, which was not boiled. Protein concentrations of boiled or unboiled 
tissue or cell lysate supernatants (homogenates) were determined. Homogenates were then 
reduced in 4x sample buffer and alkylated by addition of 20mM iodoacetamide for 1 hour at 
room temperature. Serial dilutions of known concentrations of homogenates and of purified 
recombinantly expressed His-tagged human CLC proteins were run next to one another on 
12% polyacrylamide-SDS gels, and then transferred onto nitrocellulose membranes (Bio-
Rad). Membranes were first incubated for 1 hour at room temperature with Odyssey blocking 
buffer (LI-COR Biosciences) diluted 1:1 in PBS, and then incubated in primary antibodies 
overnight, followed by incubation with secondary antibodies for 1-2 hours after 3-4 washes. 
Signal intensities of immunoblot bands were quantified using ImageJ. The amount of CLC in 
each tissue or cell homogenate was then determined using a standard curve produced from 
signals of adjacent purified protein samples quantified in the same way. Analysis was 
restricted to signals from dilutions in the linear range with an R2 value of at least 0.8, except 
for spleen homogenate where values of 0.73 were used due to the limited availability of 
sample for titrations. For quantification of pSmad2/3 and Smad2/3 the signal intensities were 
normalized to the intensity of the CHC17 signals per total protein of lysate. 
The following primary antibodies, at the noted concentrations and dilutions, were 
used: mouse monoclonal antibody (MAb) anti-CHC17 (2µg/ml, TD.1)  (41), MAb anti-CLCa 
(5µg/mL, X16) (41) or rabbit anti-CLCa (1:1000, Proteintech), rabbit anti-CLCb (1:1000, 
Proteintech), MAb anti-CLCb (2µg/mL, LCB.1) (41), mouse anti-β-actin (1:5000, Sigma), 
mouse anti-α-tubulin (1:10,000, Sigma), biotin-conjugated goat anti-mouse TGFβR2 (1:1000, 
R&D), biotin-conjugated mouse anti-α-tubulin (1:3000, eBiosciences), rabbit anti-pSmad2/3 
(1:1000, Cell Signaling Tech) and rabbit anti-Smad2 (1:1000, Life Technologies). Primary 
antibodies were detected with the following secondary antibodies or streptavidin at the 
dilutions indicated: donkey anti-rabbit IgG IRDye700DX (1:1000, Rockland), donkey anti-
mouse IgG IRDye800 (1:1000, Rockland), Streptavidin IRDye 800 (1:10,000, LiCor). For 
detection of anti-pSmad2/3 and anti-Smad2, stabilized goat anti-rabbit IgG HRP-conjugated 
antibody (1:4000, Pierce) was used. 
 
Flow cytometry. DAPI or Fixable Viability Dye eFluor® 780 (eBioscience) were used to 
exclude the dead cells. For GC B cell identification, cells were labeled with APC-Cy7- or 
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PerCPCy5.5-conjugated anti-B220 (clone RA3-6B2, BioLegend), PerCPCy5.5- or Pacific 
Blue-conjugated anti-IgD (clone IA6-2, BioLegend), PE-Cy7–conjugated anti-CD95 (clone 
Jo2; BD Biosciences), FITC or Alexa Fluor647-conjugated anti-GL7 antigen (T&B cell 
activation antigen or Ly-77, clone GL7, BioLegend). For immunoglobulin isotype detection 
the following antibodies were used: anti-IgG1 (Bio-IgG1, BioLegend) with Streptavidin-
Brilliant Violet 605 (BioLegend) or FITC-IgG1 (BioLegend) and anti-IgA (PE-IgA, Southern 
Biotech). To analyze mixed bone marrow chimeras, Pacific Blue-, PE-, FITC-, BV605-
conjugated anti-CD45.1 (clone A20, BioLegend) or anti-CD45.2 (clone 104, BioLegend) 
antibodies were used. For labeling TGFβR2 on murine B cells, PE- (FAB532P, R&D) or 
biotin (BAF532, R&D)-conjugated anti-mouse TGFβR2 antibodies were used. Streptavidin-
Brilliant Violet 605 (BioLegend) was used to detect the biotin-conjugated primary antibody. 
For CXCR4 and CXCR5 labeling, biotin-labeled-rat anti-mouse CXCR4 (BD Biosciences) 
and anti-mouse CXCR5 (BD Biosciences) antibodies were used. Streptavidin-Brilliant Violet 
605 (BioLegend) was used to detect the biotin-conjugated primary antibody. Data were 
acquired on an LSRII flow cytometer (BD Biosciences) and analyzed with FlowJo (Tree 
Star).  
 
Internalization assays. To study internalization of DOR and β2AR, stable transfectants of 
HEK293 cells expressing FLAG-tagged versions of these receptors (30, 31) were first 
washed with serum-free medium, and then incubated with serum-free medium for 15 
minutes at 37°C. Agonist ligand (10µM DPDPE for DOR or isoproterenol for β2AR) diluted in 
serum-free medium was then added to the cells at specified time points, after which cells 
were placed at 37°C and allowed to internalize the receptor for the indicated times. Control 
cells were left untreated and remained at 37°C. Then, agonist-treated and control cells were 
immediately placed on ice and washed once with cold PBS, after which they were labeled 
with anti-FLAG M1 antibody (Sigma) directly conjugated to Alexa Fluor-647 (using a kit from 
Life Technologies) for 30 min at 4°C. Cells were transferred to tubes by gentle pipetting, 
washed once with 4°C PBS, then suspended in 0.2% BSA in PBS at 4°C for FACS analysis.  
 For analysis of transferrin receptor internalization, stably transfected HEK293 cells 
above were serum starved and then labeled with mouse anti-TfR antibody (1:300, BD) 
diluted in 0.2% BSA in PBS for 30 min at 4°C. Cells were then placed on ice, washed twice 
with 4°C PBS, and then maintained in 0.2% BSA in PBS at 4°C for the remainder of the 
experiment. Cells were removed from ice and placed at 37°C for specified time points to 
allow labeled receptor to internalize, after which cells were placed back on ice, then 
incubated with Alexa Fluor-555 goat anti-mouse Ig antibody (1:500, Life Technologies) for 30 
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min at 4°C. Cells were transferred to tubes by gentle pipetting, washed once with 4°C PBS, 
then suspended in 0.2% BSA in PBS for FACS analysis.    
              For CXCR4 or CXCR5 internalization of mesenteric lymph node (mLN) B cells, the 
mLNs were harvested into pre-warmed internalization buffer (RPMI supplemented with 0.5% 
fatty acid-free BSA, 10mM Hepes, glutamine and antibiotics). Lymphocytes were then 
isolated by mechanical disaggregation through a 80-µm nylon sieve at room temperature. 
After two washes with internalization buffer, cells were re-suspended in internalization buffer 
at 107/ml. Cells were incubated in a 37°C water bath for 30 min. 90µl cell suspensions were 
added to tubes containing 10ml internalization buffer only, SDF1 (1µg/ml) or CXCL13 (10 
µg/ml) to reach the working concentration of SDF1 (100ng/ml), or CXCL13 (1 µg/ml). Cells 
were incubated for indicated times, and then 100µl 4°C internalization buffer was added to 
the tubes, which were immediately placed on ice. After internalization, cells were pelleted, 
washed and labeled with biotinylated anti-CXCR4 (Bio-CXCR4, 1:100, BD Biosciences) or 
biotinylated anti-CXCR5 (Bio-CXCR5, 1:50, BD Biosciences). After staining with 
Streptavidin-Brilliant Violet 605 (1:200, BioLegend), the cells were analyzed by FACS. DAPI 
labeling was used to exclude dead cells by gating.   
For TGFβR2 internalization, HEK293T cells co-transfected with plasmid encoding 
TGFβR2-IRES-GFP and siRNA were labeled with goat anti-human TGFβR2 antibody (1:250, 
R&D systems) diluted in DMEM supplemented with 10mM Hepes for 30 min on ice, then 
washed twice with 4°C DMEM + HEPES, and placed at 37°C for specified times to allow 
labeled receptor to internalize, after which cells were placed on ice then incubated with 
Alexa Fluor-568-conjugated secondary donkey anti-goat IgG antibody (1:500, Life 
Technologies) for 30 min on ice in the dark, and washed twice with 4°C DMEM + HEPES. 
Cells were transferred to tubes by gentle pipetting, washed once with 4°C PBS, then 
suspended in 0.2% BSA in PBS + DAPI for FACS analysis. GFP-positive cells were gated to 
identify cells for TGFβR2 internalization analysis. 
 
mRNA quantification. Total RNA was isolated with RNeasy Micro Kit or RNeasy Mini Kit 
(Qiagen, Venlo, The Netherlands). cDNA was synthesized by using MMLV reverse 
transcriptase and random primers (Life Technologies). Real-time PCR was carried out using 
a StepOnePlus real-time PCR system (Applied Biosystems, Foster City, CA) with SYBR 
Green PCR Master Mix (Applied Biosystems) and the appropriate primer pairs. Relative 
mRNA abundance of target genes was determined by subtracting the threshold cycle for the 
internal reference mRNA encoding hypoxanthine guanine phosphoribosyl transferase 1 
(HPRT1) from that of the target. The primer pairs used for real-time PCR are as follow: For 
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CLTA, forward primer 5'-ATGCTGTTGACGGAGTGATGA-3', and reverse primer 5'-
CCACTTACGGATACTTTCAGGCT-3'. For CLTB, forward primer 5'-GAAAGCGA 
GATTGCTGGCATC-3' and reverse primer 5'-CGTTAGCCTCCTGAAACACATC-3'. For 
CLTC (gene encoding CHC17), forward primer 5'-   AGATTCTGCCCATTCGCTTTC-3' and 
reverse primer 5'-TCAGTGCAATCACTTTGCTGG-3'; For HPRT1, forward primer 5'-
AGGTTGCAAGCTTGCTGGT-3' and reverse primer 5'-
TGAAGTACTCATTATAGTCAAGGGCA-3', (Integrated DNA Technologies).  
 
Figure Legends 
 
Figure S1. Genetic deletion of CLCa in mice and quantification of CLC isoforms in 
murine tissues. (A) CLTAflox genetic construct for targeted deletion of CLTA by ACTB-Cre-
mediated deletion of exon 1 flanked by LoxP sites (CLTAko). Exons are numbered and are 
indicated by black boxes. White box indicates 5’ untranslated region.  Primers are 
designated by orange, blue and black triangles. Black lines below each allele denote PCR 
products generated from the CLTA+ (311bp) and CLTAko (682bp) alleles. (B) PCR analysis 
of genomic DNA from wild type (WT) (CLTA+/+, +/+), heterozygous (CLTAko/+, -/+) and 
homozygous knockout (KO) (CLTAko/ko, -/-) mice. (C) Indicated tissues from homozygous 
CLCa WT and KO (CLTAko/ko) littermates were homogenized and analyzed by 
immunoblotting for CLCa and CLCb using isoform-specific antibodies with CLCa in green 
and CLCb in red. nCLCa and nCLCb are the neuron-specific splice variants. Migration 
position of molecular mass of marker (kilodaltons, kD) is indicated (right). (D) Total 
splenocytes and B cells isolated from spleens of wild-type (WT) or CLCa-null (KO) mice 
were lysed and analyzed by immunoblotting for proteins indicated by arrowheads. Migration 
positions of molecular mass of markers (kilodaltons, kD) is indicated (right). (E) Indicated 
tissues from homozygous WT and KO littermates were homogenized and immunoblotted for 
CHC17 and α-tubulin. For each tissue analyzed, equal protein amounts of homogenate from 
WT or KO mice were compared. (F) Level of CHC17 mRNA measured by quantitative PCR 
analysis of the indicated tissues (Pp, Peyer’s patch; mLN, mesenteric lymph node) from WT 
and KO mice. Expression level was normalized to mRNA encoding hypoxanthine guanine 
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phosphoribosyl transferase 1 (mean ± SEM of n=3, except n=2 for brain cortex). (G) 
Representative immunoblots for quantification of CLC isoforms in homogenates of brain 
tissue and spleen cells from WT and KO mice, detected using isoform-specific antibodies 
with CLCa in green and CLCb in red. nCLCa and nCLCb are the neuron-specific splice 
variants. Tissue samples were serially diluted and compared to serial dilutions of purified 
recombinantly-produced CLCs to calibrate the blotting signal. The His-tag on the 
recombinant CLCs slows their migration compared to the untagged equivalents in the 
homogenates. Migration position of molecular mass markers is indicated (left) in kilodaltons 
(kD). (H) Representative plots of fluorescence signals generated from isoform-specific 
immunoblots of the indicated tissues (no lines) or purified proteins (lines drawn for slope 
calculation). The concentrations reported in Fig. 1A were established from n=3 of these 
analyses for each tissue. 
 
Figure S2. Flow cytometry gating strategy for analysis of follicular and germinal 
center B cells. (A) Lymphocytes isolated from Peyer’s patches of wild-type (WT) and CLCa-
null (KO) littermates were immunolabeled for the markers indicated. B220-positive cells were 
first gated on CD95high and IgDlow expression, and then gated on GL7high expression to 
identify germinal center B cells (GC B). Follicular B cells (Fo B) were identified by CD95low 
and IgDhigh expression. (B) Representative flow cytometric analysis of the frequency of IgA 
and IgG1-expressing GC B cells (gated as in A) in Peyer's patches of WT and KO 
littermates, detected by staining for each antibody isotype. (C) Mixed bone marrow chimeras 
(WT/B6 and KO/B6) were generated by injection of cells from WT or KO mice (CD45.2+) 
mixed in a 1:1 ratio with bone marrow cells from C57BL/6 (B6) mice (CD45.1+ CD45.2+) into 
irradiated recipient B6 mice (CD45.1+). GC and Fo B cell populations from Peyer’s patches 
of chimeric animals were identified based on the gating scheme shown in A and a 
representative analysis of the percentage of cells derived from each donor, assessed by 
labeling for CD45.1 and CD45.2 surface markers, is shown. (D) Representative flow 
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cytometric analysis of the frequency of IgA and IgG1-producing GC B cells in Peyer's 
patches shown for each donor population in the WT/B6 (top pair) or KO/B6 (bottom pair) 
mixed chimeras. For B-D, numbers indicate the percentage of cells in the respective 
quadrant or gate. 
 
Figure S3. Expression of TGFβR2 and B220 detected by flow cytometry and analysis 
of TGFβR2 signaling. (A) Representative flow cytometry analysis of surface expression of 
TGFβR2 and B220 on germinal center (GC) and follicular (Fo) B cells from Peyer's patches 
(left) and total B cells from spleen (right) of wild type (WT) and CLCa-null (KO) littermates 
(gating as in Figure S2A). X-axes represent fluorescence intensities and y-axes are relative 
cell counts (normalized to the maximum cell count in each experiment). (B) Quantification of 
B220 surface fluorescent labeling from Peyer’s patches (left) and spleen (right) of WT and 
KO littermates. Data is presented as geometric mean fluorescent intensity (MFI; n>11 for 
Peyer’s patches and n=7 for spleen, *P<0.01, **P<0.001, unpaired t test). (C) 
Representative flow cytometry analysis of surface levels of TGFβR2 and B220 on GC B and 
Fo B cells in Peyer's patches from WT/B6 and KO/B6 chimera mice (produced as in Fig. S2 
C), separated by donor genotype (B6, blue; WT, black; KO, red; background staining, tinted 
peak). X-axes depict fluorescence intensities and y-axes depict cell count normalized to the 
maximum count. (D) The ratio of the MFI of WT or KO donor cells (CD45.2+) to the MFI of 
B6 donor cells (CD45.1+CD45.2+) for staining of B220 is shown for GC and Fo B cells (mean 
± SEM of n=10 from at least 3 pairs of different donors for WT/B6 and KO/B6 chimeras, 
**P<0.05, ***P<0.001, unpaired, t-test). (E and F) Total splenocytes and purified spleen B 
cells from WT and KO littermates were lysed and analyzed by immunoblotting for CHC17, 
CLCa, phosphorylated Smad2/3 (pSmad2/3) in (E) and total Smad2/3 in (F). Representative 
blots are shown. Migration position of molecular mass markers is indicated (kilodaltons, kD). 
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Fig S4. Assessment of CXCR4 and CXCR5 surface levels and internalization by flow 
cytometry. (A) Representative flow cytometry analysis of surface levels of CXCR4 or B220 
on germinal center (GC) B cells from mesenteric lymph nodes (mLN) of wild-type (WT) and 
CLCa-null (KO) littermates. (B) Mean fluorescence intensities (MFI) of CXCR4 and B220 
surface labeling of GC B cells from Peyer’s patches and mLN from multiple animals as in 
(A). (n>11 for Peyer’s patches, n>20 for mLN; *P<0.01, unpaired t test, KO compared to WT 
mice). (C) Representative flow cytometry analysis of surface levels of CXCR4 or B220 on 
GC B cells from Peyer’s patches in WT/B6 and KO/B6 chimeras, separated by donor 
genotype (B6, blue; WT, black; KO, red). (D) Ratios of the mean fluorescence intensity (MFI) 
of CXCR4 on wild-type (WT) or CLCa-null (KO) donor cells (CD45.2+) to CXCR4 on C57Bl/6 
(B6) (CD45.1+CD45.2+) donor cells for germinal center (GC) B cells from mLNs of WT/B6 
and KO/B6 chimeras (mean ± SEM; n>24, from at least 3 pairs of different donors for mixed 
chimera mice, ***P<0.001, unpaired, t-test). (E) B cells isolated from mLNs of WT and KO 
littermates were treated with PBS for 30 minutes at 37°C (no agonist) or 100ng/mL SDF1 
(Stromal cell-derived factor 1) for 10 or 30 minutes at 37°C, then immediately chilled and 
CXCR4 surface levels on GC and follicular (Fo) B cells assessed by flow cytometry. One 
representative experiment is shown. X-axes represent fluorescence intensities and y-axes 
represent cell count normalized to the maximum count. (F) B cells isolated from WT/B6 or 
KO/B6 chimeras were treated with 100ng/mL SDF1 (Stromal cell-derived factor 1) for 10 or 
30 minutes at 37°C, then immediately chilled and CXCR4 surface levels on GC and Fo B 
cells assessed by flow cytometry. Ratio of MFI’s of surface CXCR4 on WT or KO donor cells 
(CD45.2+) to surface CXCR4 on B6 donor cells (CD45.1+CD45.2+) from each chimera is 
shown for the indicated time points (mean ± SEM of n=6 WT and n=7 KO mice from 4 
independent experiments, *P<0.01, ***P<0.001, two-way ANOVA with Bonferroni post tests).  
(G) B cells isolated from the mLNs of WT and KO littermates were treated with PBS for 30 
minutes at 37°C (no agonist) or 1µg/ml CXCL13 for 10 or 30 minutes at 37°C, after which 
they were immediately chilled and CXCR5 surface levels on GC and Fo B cells assessed by 
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flow cytometry. One representative experiment is shown. X-axes indicate fluorescence 
intensities and y-axes represent relative cell counts normalized to the maximum count. (H) B 
cells isolated from WT/B6 or KO/B6 chimeras were treated with CXCL13 for 10 or 30 
minutes at 37°C, after which they were immediately chilled and CXCR5 surface levels on GC 
and Fo B cells assessed by flow cytometry. Ratios of MFI’s of surface CXCR5 on WT or KO 
donor cells (CD45.2+) to surface CXCR5 on B6 donor cells (CD45.1+CD45.2+) from each 
chimera is shown for the indicated time points (mean ± SEM of n=2 and n= 3 KO mice from 
2 independent experiments). 
 
Fig S5. siRNA treatment of HEK293 stable transfectants expressing FLAG-tagged G-
protein-couple receptors and representative flow cytometry data for receptor 
internalization assays. (A & B) HEK293 cells that stably expressed (A) FLAG-tagged β2-
adrenergic receptor (FLAG-β2AR) or (B) FLAG-tagged δ-opioid receptor (FLAG-DOR) were 
treated with the siRNA targeting CHC17 or CLCa and CLCb (CLCab) or scrambled siRNA 
(control) for 72 hours and then cell lysates were analyzed by immunoblotting for levels of the 
indicated proteins (left). Migration position of molecular mass markers is indicated at the 
right (kilodaltons, kD). (C & E) Representative flow cytometry analysis of receptor levels 
detected with anti-FLAG antibody on HEK293 cells stably expressing FLAG-tagged δ-opioid 
receptor (FLAG-DOR) or FLAG-tagged β2-adrenergic receptor (FLAG-β2AR) at indicated 
times after treatment at 37°C with agonists (DPDPE for FLAG-DOR cells or isoproterenol for 
FLAG-β2AR cells; time 0, black; 5 min, green; 20 min, red). Before exposure to agonist, cells 
were pre-treated for 72 hours with control siRNA or siRNA targeting CHC17 or CLCab, as 
indicated above each plot. X-axes indicate fluorescence intensities and y-axes represent 
relative cell counts normalized to the maximum count. (D & F) Representative flow cytometry 
analysis of endogenous transferrin receptor (TfR) surface levels on the si-RNA-treated 
stable transfectants analyzed in C & E (not agonist treated), labeled with primary antibody to 
TfR at 4°C at time zero, detected with secondary antibody at the indicated times after 
! 10 
incubation at 37°C. X-axes indicate fluorescence intensities and y-axes represent relative 
cell counts normalized to the maximum count. 
- 682 
bp
- 311 
+ /
 +
- / 
+
 - /
 - 
A B
21
CLTA       allele
LoxP
2
CLTA     allele
LoxP
LoxP
311 bp
21
CLTA     allele
682 bp
wt
ko
flox
CLTAwt
CLTAko
C Brain Liver Heart Spleen Adrenals Muscle Kidney
WT KO WT KO WT KO WT KO WT KO WT KO WT KO
- 37
kD
nCLCa
nCLCb
CLCa
CLCb
D
CHC17
α-tubulin
-170
-55
kD
Brain Spleen Heart Muscle LiverKidney
WT KO WT KO WT KO WT KO WT KO WT KO
CLCa
α-tubulin
CHC17
WT  KO  WT  KO  
spleen B cells
250 
150 
75 
50 
37 
kD E
0
1
2
3
Pp
WT
KO
F
WT Spleen KO Spleenpurified CLCa/CLCb purified CLCa/CLCb
CLCa
CLCb
CLCa
CLCb
CLCa
CLCb
CLCa
CLCb
nCLCa
nCLCb
nCLCa
nCLCb
WT Brain purified nCLCa/nCLCb
purified CLCa/CLCb
nCLCa
CLCa CLCa
KO Brain purified nCLCa/nCLCb
purified CLCa/CLCb
nCLCb
nCLCb
CLCb
nCLCa
nCLCb
CLCa
CLCb
G
CLCb
nCLCb
CLCb
- 37
kD
- 37
- 37
kD
kD
- 37
- 37
kD
- 37
- 37
kD
kD
- 37
H
mL
N
Sp
lee
n
He
art
Liv
er
co
rte
x
Br
ain
C
H
C
17
 m
R
N
A
(n
or
m
al
iz
ed
)
flu
or
es
ce
nt
 in
te
ns
ity
 (a
.u
.)
15000
10000
5000
0
15000
10000
5000
0
15000
10000
5000
0
15000
10000
5000
0
15000
10000
5000
0
15000
10000
5000
0
15000
10000
5000
0
15000
10000
5000
0
15000
10000
5000
0
μg tissue or ng CLC
0 20 40 60 80 0 20 40 60 80
μg tissue or ng CLC
μg tissue or ng CLC
0 10 20 30 40
μg tissue or ng CLC
0 10 20 30 40
μg tissue or ng CLC
0 5 10 15 20
μg tissue or ng CLC
0 5 10 15 20
20000
15000
10000
5000
0
20000
flu
or
es
ce
nt
 in
te
ns
ity
 (a
.u
.)
flu
or
es
ce
nt
 in
te
ns
ity
 (a
.u
.)
Brain
Spleen
WT KO
20000 20000
0 2 10 15 20
μg tissue or ng CLC
25 0 2 10 15 20
μg tissue or ng CLC
25
0 10 20
μg tissue or ng CLC
30 0 10 20
μg tissue or ng CLC
30
WT KO
Liver
Heart
tissue nCLCa
purified nCLCa
tissue nCLCa
purified nCLCa
tissue nCLCa
purified nCLCa
tissue nCLCa
purified nCLCa
Fo B 
GC B 
48.8
54.0
41.1
78.9
Peyer’s patches 
Ig
G
1
GC B 
35.5
19.1
WT
IgA
Ig
G
1 20.6
43.4
14.6
39.9
20.5
24.2
9.62
56.3
B6 WT 
KO
Fo B 
GC B 
Ig
D
CD95
B2
20
GL7
B220+
 WT / B6
C
D
45
.1
CD45.2
49.2
BA
D
B6
103 104 1051020
0
102
103
104
105
10 104 1051020
0
102
103
104
105
10 104 10510-3 0
0
10-3
103
104
105
3
3
10 10410510210 31010
100
101
102
103
104
105
100
101
102
103
104
105
10 10410510210 31010
100
101
102
103
104
105
10 10410510210 31010
100
101
102
103
104
105
10 10410510210 31010
10 104 1051020
0
102
103
104
105
3 10 104 1051020
0
102
103
104
105
3
10 104 1051020 310 104 1051020 3
0
102
103
104
105
0
102
103
104
105
44.9
53.1
18.1
35.5
19.1
KO
10 104 10510-3 0
0
10-3
103
104
105
3
45.6
IgA
10.5
C
 KO / B6
WT KO
B
22
0 
M
FI
 X
 1
00
WT KO WT KO
0
20
40
60
80
B
22
0 
M
FI
 X
 1
00
FoB GCB
Peyer’s patches Spleen
D
0
0.5
1.0
1.5
 
B
B
22
0 
M
FI
 X
 1
00
B
22
0 
M
FI
 ra
tio
C KO / B6 
Fo B GC B
WT / B6 
GC BFo B 
TGFβR2
B220
B6
KO
B6
 WT
R
el
at
iv
e 
C
ou
nt
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
R
el
at
iv
e 
C
ou
nt
A
TGFβR2
B220
GC B Fo B 
Peyer’s patches Spleen
B cell KO
 WT
R
el
at
iv
e 
C
ou
nt
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
103104105102101100 103104105102101100 103104105102101100
103104 105102101100 103 104105102101100 103 104105102101100
R
el
at
iv
e 
C
ou
nt
103104105102101100 103104105102101100
103104105102101100 103104105102101100 103104105102101100
103104105102101100
103104105102101100
103104105102101100
B
22
0 
M
FI
 ra
tio
WT/B6 KO/B6WT/B6 KO/B6
GC B Fo B E
WT  KO
spleen
CHC17
pSmad2/3
CLCa
250
150
37
25
75
50
WT  KO
B cell
kD
F
WT   KO WT   KO
250
150
37
25
75
50
kD
spleen B cell
CHC17
Smad2/3
CLCa
0
0.5
1.0
1.5
0
20
40
60
80
CCXCR4 B220
WT / B6 KO / B6
A
CXCR4
B220
B
0
10
20
30
40
M
FI
 o
f G
C
 B
 x
10
0
WT KO
WT KO
100
200
300
0
0
10
20
30
40
M
FI
 o
f G
C
 B
 x
10
0
50
WT KO
WT KO
0
10
20
30
WT / B6 KO  / B6
R
el
at
iv
e 
C
ou
nt
0
20
40
60
80
100
0
20
40
60
80
100
102 103104 105
mLN
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
101100
102 103104 105101100
102 103104 105101100 102 103104 105101100 102 103104 105101100 10
2 103104 105101100
R
el
at
iv
e 
C
ou
nt
R
el
at
iv
e 
C
ou
nt
R
el
at
iv
e 
C
ou
nt
WT
KO
D
Fo B GC B Fo B GC B No agonist
10 min
30 min
PBS SDF1
WT
R
el
at
iv
e 
C
ou
nt
0
20
40
60
80
100
KO
0
20
40
60
80
100
100 103104 105101102 100 103104105101102 100 103 104105101 102 100 103104105101102
0
20
40
60
80
100
0
20
40
60
80
100
100 103104 105101102 100 103104 105101102 100 103104105101102 100 103 104105101102
R
el
at
iv
e 
C
ou
nt
CXCR4
E
WT
Fo B GC B Fo B GC B
PBS CXCL13
R
el
at
iv
e 
C
ou
nt
0
20
40
60
80
100
0
20
40
60
80
100
R
el
at
iv
e 
C
ou
nt
KO 
100 103104105101102 100 103104 105101102 10
0 103104105101102 100 103104105101102
100 103104105101102 100 103104105101102 100 103104105101102 100 103104105101102
0
20
40
60
80
100
0
20
40
60
80
100
CXCR5
* *
Peyer’s patches mLN
CXCR4
B220
0
0.5
1.0
1.5 *** ***
%
 s
ur
fa
ce
 C
X
C
R
4
(C
D
45
.2
+/
B
6)
 
0
0.5
1.0
1.5
* ***
GC B
Fo BF
%
 s
ur
fa
ce
 C
X
C
R
4
(C
D
45
.2
+/
B
6)
 
10 min 30 min
WT/B6 WT/B6KO/B6 KO/B6
10 min 30 min
WT/B6 WT/B6KO/B6 KO/B6
H
0
0.5
1.0
1.5
0
0.5
1.0
1.5
GC B
Fo B
%
 s
ur
fa
ce
 C
X
C
R
5
(C
D
45
.2
+/
B
6)
 
%
 s
ur
fa
ce
 C
X
C
R
5
(C
D
45
.2
+/
B
6)
 
10 min 30 min
WT/B6 WT/B6KO/B6 KO/B6
10 min 30 min
WT/B6 WT/B6KO/B6 KO/B6
0
0.5
1.0
1.5
2.0
mLN
***
M
FI
 ra
tio
CXCR4 B220
WT/B6 WT/B6KO/B6 KO/B6
G
No agonist
10 min
30 min
-170
-55
-35
-35
kD
-55
CHC17
CLCa
CLCb
α-tubulin
α-tubulin
Co
ntr
ol 
CH
C1
7 
CL
Ca
b A B
-170
-55
-35
kD
-35
CHC17
CLCa
α-tubulin
CLCb
Co
ntr
ol 
CH
C1
7 
CL
Ca
b 
siRNA:siRNA:
0 10 10 103 4 5 0 10 10 103 4 5 0 10 10 103 4 5
FLAG- β2AR
0
100
150
200
50
250
0
60
90
120
30
0
100
150
50
co
un
t
Control CHC17 CLCab 
0
100
150
200
50
250
co
un
t
0 10 10103 4 5 0 10 10 103 4 5 0 10 10 103 4 5
TfR
0
100
150
200
50
250
0
100
150
200
50
250
Control CHC17 CLCab 
0’
0’
5’ 
20’ 
20’ 
5’ 
0
100
150
200
50
0 10 10 103 4 5
0
100
150
50
0 10 10 103 4 5 0 10 10 103 4 5
0
100
150
50
Control CHC17 CLCab 
FLAG- DOR
co
un
t
0
120
30
60
90
0 10 10 103 4 5 0 10 10 103 4 5 0 10 10 103 4 5
0
120
30
60
90
0
100
20
40
60
80
co
un
t
TfR
Control CHC17 CLCab 
0’
5’ 
20’ 
0’
5’ 
20’ 
C
D
E
F
